WO2006010051A3 - Methods of diagnosing & treating diabetes and insulin resistance - Google Patents

Methods of diagnosing & treating diabetes and insulin resistance Download PDF

Info

Publication number
WO2006010051A3
WO2006010051A3 PCT/US2005/024365 US2005024365W WO2006010051A3 WO 2006010051 A3 WO2006010051 A3 WO 2006010051A3 US 2005024365 W US2005024365 W US 2005024365W WO 2006010051 A3 WO2006010051 A3 WO 2006010051A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
insulin resistance
treating diabetes
diabetes
Prior art date
Application number
PCT/US2005/024365
Other languages
French (fr)
Other versions
WO2006010051A2 (en
Inventor
Shonna A Moodie
Grace Perez
Fang Zhang
Original Assignee
Metabolex Inc
Shonna A Moodie
Grace Perez
Fang Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc, Shonna A Moodie, Grace Perez, Fang Zhang filed Critical Metabolex Inc
Priority to JP2007520559A priority Critical patent/JP2008505648A/en
Publication of WO2006010051A2 publication Critical patent/WO2006010051A2/en
Publication of WO2006010051A3 publication Critical patent/WO2006010051A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions and methods for diagnosing and treating diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of the polynucleotides or polypeptides of the invention and using those modulators to treat diabetes, as well as methods of diagnosing diabetes by measuring the levels of the polynucleotides or polypeptides of the invention in a patient.
PCT/US2005/024365 2004-07-07 2005-07-07 Methods of diagnosing & treating diabetes and insulin resistance WO2006010051A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007520559A JP2008505648A (en) 2004-07-07 2005-07-07 Methods for diagnosis and treatment of diabetes and insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58635804P 2004-07-07 2004-07-07
US60/586,358 2004-07-07

Publications (2)

Publication Number Publication Date
WO2006010051A2 WO2006010051A2 (en) 2006-01-26
WO2006010051A3 true WO2006010051A3 (en) 2007-02-22

Family

ID=35785769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024365 WO2006010051A2 (en) 2004-07-07 2005-07-07 Methods of diagnosing & treating diabetes and insulin resistance

Country Status (2)

Country Link
JP (1) JP2008505648A (en)
WO (1) WO2006010051A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811242A (en) * 1995-10-24 1998-09-22 Tokuyama Corporation Marker and reagent for diabetes mellitus and diabetes mellitus complication
US6074822A (en) * 1995-11-03 2000-06-13 Board Of Trustees Operating Michigan State University Method for testing for risk of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811242A (en) * 1995-10-24 1998-09-22 Tokuyama Corporation Marker and reagent for diabetes mellitus and diabetes mellitus complication
US6074822A (en) * 1995-11-03 2000-06-13 Board Of Trustees Operating Michigan State University Method for testing for risk of diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILKIN T. ET AL.: "Markers for insulin dependent diabetes: towards early detection", BRIT. MED. J., vol. 293, 22 November 1986 (1986-11-22), pages 1323 - 1326, XP003008378 *

Also Published As

Publication number Publication date
WO2006010051A2 (en) 2006-01-26
JP2008505648A (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
WO2006097793A3 (en) Compositions capable of facilitating penetration across a biological barrier
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
IL198922A0 (en) Chemical compounds and uses
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
WO2008055491A3 (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2008027687A3 (en) Use of tenecteplase for treating acute ischemic stroke
WO2007092640A3 (en) Antibodies that bind par-2
WO2008131361A3 (en) Biosensors for measuring analytes in the interstitial fluid
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2003103597A3 (en) Methods of diagnosing & treating diabetes and insulin resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007520559

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase